Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risuteganib - Allegro Ophthalmics

Drug Profile

Risuteganib - Allegro Ophthalmics

Alternative Names: ALG-1001; AM-011; Integrin Peptide Therapy; Luminate

Latest Information Update: 27 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allegro Ophthalmics
  • Developer Allegro Ophthalmics; Hanmi Pharmaceutical
  • Class Angiostatic proteins; Anti-inflammatories; Carboxylic acids; Eye disorder therapies; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Dry age-related macular degeneration; Retinal disorders; Wet age-related macular degeneration
  • No development reported Retinitis pigmentosa

Most Recent Events

  • 26 Sep 2023 National Medical Products Administration approves Clinical Trial Application (CTA) for risuteganib in age-related macular degeneration (Dry AMD)
  • 26 Sep 2023 AffaMed Therapeutics plans a phase III trial for age-related macular degeneration in China
  • 12 Apr 2023 Allegro Ophthalmics intends to file marketing application
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top